That's my prediction, which I think is a reasonable one. After the 50% haircut that Amicus got after it's failed phase 3, Glaxo can probably shave a couple hundred mill off the price. Maybe $400-$500 mill instead of $600-$700 mill. I'll take $400 mill. That's a price of $8.08. $500 mill would be just over $10 a share.